Interestingly, Rui et al. [219] demonstrated that JAK1 contributes to tumor growth and survival of ABC-DLBCL cells through a regulatory mechanism dependent on phosphorylation of histone H3 at tyrosine 41, which supports the development of JAK1 inhibitors for ABC-DLBCL therapy. Here, JAK1 is linked to diffuse large B-cell lymphoma.